Two Sigma Advisers
VKTX icon

Two Sigma Advisers’s Viking Therapeutics VKTX Stock Holding History

Two Sigma Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,129,228
Closed -$74.9M – 2092
2025
Q4 		$74.9M Buy
2,129,228
+574,100
+37% +$20.3M 0.15% 149
2025
Q3 		$40.9M Buy
1,555,128
+463,700
+42% +$13.8M 0.08% 200
2025
Q2 		$28.9M Buy
+1,091,428
New +$28.7M 0.06% 266
2023
Q4 		– Sell
-10,628
Closed -$118K – 2656
2023
Q3 		$118K Buy
+10,628
New +$152K ﹤0.01% 2191
2023
Q2 		– Sell
-896,528
Closed -$14.9M – 2675
2023
Q1 		$14.9M Sell
896,528
-50,500
-5% -$522K 0.04% 413
2022
Q4 		$8.9M Buy
947,028
+40,400
+4% +$180K 0.02% 550
2022
Q3 		$2.47M Sell
906,628
-214,400
-19% -$702K 0.01% 1064
2022
Q2 		$3.24M Buy
1,121,028
+13,000
+1% +$32.2K 0.01% 966
2022
Q1 		$3.32M Buy
1,108,028
+229,600
+26% +$824K 0.01% 991
2021
Q4 		$4.04M Sell
878,428
-60,400
-6% -$339K 0.01% 860
2021
Q3 		$5.9M Sell
938,828
-45,400
-5% -$280K 0.02% 710
2021
Q2 		$5.9M Sell
984,228
-42,000
-4% -$249K 0.02% 788
2021
Q1 		$6.49M Buy
1,026,228
+562,700
+121% +$3.96M 0.02% 749
2020
Q4 		$2.61M Buy
463,528
+382,000
+469% +$2.31M 0.01% 1126
2020
Q3 		$474K Buy
81,528
+42,028
+106% +$289K ﹤0.01% 1848
2020
Q2 		$285K Buy
+39,500
New +$262K ﹤0.01% 2137
2019
Q1 		– Sell
-13,400
Closed -$103K – 2464
2018
Q4 		$103K Sell
13,400
-18,800
-58% -$225K ﹤0.01% 2219
2018
Q3 		$561K Buy
32,200
+8,000
+33% +$95.2K ﹤0.01% 1750
2018
Q2 		$230K Buy
24,200
+5,400
+29% +$35.9K ﹤0.01% 2174
2018
Q1 		$82K Buy
+18,800
New +$104K ﹤0.01% 2236

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Two Sigma Advisers's VKTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 2,129,228 shares — an estimated $74.9M sold.

Two Sigma Advisers first reported a position in VKTX in Q1 2018 and held it in 20 quarters. The position peaked at $74.9M in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 2,129,228 Viking Therapeutics shares in Q1 2026, an estimated $74.9M.
  • Two Sigma Advisers first reported a position in Viking Therapeutics in Q1 2018 and held it in 20 quarters.
  • Two Sigma Advisers's Viking Therapeutics position peaked at $74.9M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.